LIMITED OFFER
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code is needed.
Advances in Clinical Chemistry
- 1st Edition, Volume 109 - August 3, 2022
- Editor: Gregory S. Makowski
- Language: English
- Hardback ISBN:9 7 8 - 0 - 3 2 3 - 9 8 8 5 1 - 3
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 9 8 8 5 2 - 0
Advances in Clinical Chemistry, Volume 109, the latest installment in this internationally acclaimed series, contains chapters authored by world-renowned clinical laboratory scient… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteAdvances in Clinical Chemistry, Volume 109, the latest installment in this internationally acclaimed series, contains chapters authored by world-renowned clinical laboratory scientists, physicians and research scientists. The serial discusses the latest and most up-to-date technologies related to the field of clinical chemistry, with this new release focusing on Biomarkers of dysfunctional visceral fat, Immunoassay Design and Biotin Interference, Orexin/Hypocretin and Major Psychiatric Disorders and more.
- Provides the most up-to-date technologies in
- clinical chemistry and clinical laboratory scienceAuthored by world renowned clinical laboratory scientists, physicians and research scientists
- Presents the international benchmark for novel analytical approaches in the clinical laboratory
Clinical Laboratory Professionals, Physicians and Research Scientists
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Preface
- Chapter One: Biomarkers of dysfunctional visceral fat
- Abstract
- 1: Introduction
- 2: What makes adipose tissue dysfunctional?
- 3: Excess lipolysis in adipose tissue: Palmitate and lipotoxicity
- 4: Dysfunctional visceral fat secretion patterns
- 5: Metabolomics
- 6: Conclusions
- Acknowledgments
- References
- Chapter Two: Biomarkers in cardiogenic shock
- Abstract
- 1: Introduction
- 2: Lactatemia in cardiogenic shock
- 3: Biomarkers of organ injury and dysfunction
- 4: Markers of metabolism
- 5: Inflammatory markers
- 6: Novel biomarkers
- 7: Summary and future perspectives
- References
- Chapter Three: Cysteine and related aminothiols in cardiovascular disease, obesity and insulin resistance
- Abstract
- 1: Introduction
- 2: Aminothiols—Characteristics, biologic function and metabolic interactions
- 3: Thiol redox status and oxidative stress
- 4: Analysis of cysteine and related aminothiols in human blood
- 5: Cysteine as a biomarker in cardiovascular disease, obesity, and insulin resistance
- 6: Summary and future perspectives
- Author contributions
- Conflicts of interest
- References
- Chapter Four: Oligoclonal bands: An immunological and clinical approach
- Abstract
- 1: Introduction
- 2: Evolution in the techniques and detection methods of IgG OCBs
- 3: Determination of IgG OCBs within the diagnostic criteria of MS: An overview
- 4: IEF as reference technique in IgG OCBs detection
- 5: A single band of IgG immunoglobulin in CSF
- 6: Prevalence of IgG OCBs and effect of latitude in MS
- 7: OCBs of IgM isotype: An overview
- 8: Clinical usefulness of IgG OCBs in neurological diseases
- 9: Summary and future perspectives
- References
- Chapter Five: Immunoassay design and biotin interference
- Abstract
- 1: Introduction
- 2: Biotin: Overview of pharmacology
- 3: Biotin supplements
- 4: Serum biotin
- 5: Biotin based immunoassays and biotin interference
- 6: Clinically significant interferences due to elevated biotin concentrations
- 7: Biotin interference in thyroid testing
- 8: Biotin interference in PTH testing
- 9: Biotin interference in troponin testing
- 10: FDA communication on biotin
- 11: Biotin interference in multiple immunoassays
- 12: Threshold biotin concentration for interference
- 13: Prevalence of clinically significant biotin interference
- 14: Mitigation of biotin interference
- 15: Conclusions
- References
- Chapter Six: Orexin/hypocretin and major psychiatric disorders
- Abstract
- 1: Introduction
- 2: Orexin and narcolepsy
- 3: Schizophrenia
- 4: Major Depressive Disorder (MDD)
- 5: Bipolar disroder
- 6: Other studies
- 7: Conclusion
- Acknowledgment
- References
- Index
- No. of pages: 234
- Language: English
- Edition: 1
- Volume: 109
- Published: August 3, 2022
- Imprint: Academic Press
- Hardback ISBN: 9780323988513
- eBook ISBN: 9780323988520
GM
Gregory S. Makowski
Dr Gregory S Makowski is a board certified clinical chemist and fellow of the National Academy of Clinical Biochemistry. Following receipt of his PhD in Biochemistry from the University of Connecticut Storrs, he pursued post-doctoral studies at the University of Connecticut School of Medicine in Farmington that culminated in his joint appointments in the School of Medicine and the Department of Laboratory Medicine at John Dempsey Hospital. He has numerous clinical and basic science publications and serves on various scientific and editorial boards. He is actively engaged in the training of Pathology residents and fellows in the Department of Pathology and Laboratory Medicine at Hartford Hospital. He currently serves as Vice President and Chief Scientific Officer for Clinical Laboratory Partners in Newington CT, USA.
Affiliations and expertise
Vice President and Chief Scientific Officer, Clinical Laboratory Partners, Newington, CT, USARead Advances in Clinical Chemistry on ScienceDirect